Verve Therapeutics, Inc. (VERV) Financial Statements (2024 and earlier)

Company Profile

Business Address 201 BROOKLINE AVENUE
BOSTON, MA 02215
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)

9/30/2023
MRQ
12/31/2022
12/31/2021
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:554,800,000360,442,000
Cash and cash equivalents115,412,00064,330,000
Short-term investments878,792,000296,112,000
Other undisclosed cash, cash equivalents, and short-term investments(439,404,000) 
Restricted cash and investments4,824,0005,237,000
Other undisclosed current assets3,535,0001,449,000
Total current assets:563,159,000367,128,000
Noncurrent Assets
Operating lease, right-of-use asset91,877,0001,839,000
Property, plant and equipment18,778,0007,224,000
Restricted cash and investments4,824,0005,237,000
Other noncurrent assets585,0002,696,000
Total noncurrent assets:116,064,00016,996,000
TOTAL ASSETS:679,223,000384,124,000
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities23,191,00020,069,000
Accounts payable2,424,0007,077,000
Accrued liabilities20,767,00012,992,000
Other undisclosed current liabilities11,904,0001,955,000
Total current liabilities:35,095,00022,024,000
Noncurrent Liabilities
Liabilities, other than long-term debt70,297,000377,000
Other liabilities283,000377,000
Operating lease, liability70,014,000 
Other undisclosed noncurrent liabilities22,899,0004,371,000
Total noncurrent liabilities:93,196,0004,748,000
Total liabilities:128,291,00026,772,000
Equity
Equity, attributable to parent550,932,000357,352,000
Common stock62,00049,000
Additional paid in capital895,801,000544,381,000
Accumulated other comprehensive loss(694,000)(228,000)
Accumulated deficit(344,237,000)(186,850,000)
Total equity:550,932,000357,352,000
TOTAL LIABILITIES AND EQUITY:679,223,000384,124,000

Income Statement (P&L) (USD)

9/30/2023
TTM
12/31/2022
12/31/2021
Gross profit:(3,907,000)(1,842,000)
Operating expenses(167,628,000)(87,067,000)
Other undisclosed operating income5,848,0001,842,000
Operating loss:(165,687,000)(87,067,000)
Nonoperating income (expense)8,353,000(33,247,000)
Other nonoperating income6,867,000142,000
Loss from continuing operations before income taxes:(157,334,000)(120,314,000)
Income tax expense(53,000) 
Other undisclosed loss from continuing operations  
Loss from continuing operations:(157,387,000)(120,314,000)
Loss before gain (loss) on sale of properties:(120,314,000)
Net loss available to common stockholders, diluted:(157,387,000)(120,314,000)

Comprehensive Income (USD)

9/30/2023
TTM
12/31/2022
12/31/2021
Net loss:(157,387,000)(120,314,000)
Comprehensive loss:(157,387,000)(120,314,000)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(466,000)(236,000)
Comprehensive loss, net of tax, attributable to parent:(157,853,000)(120,550,000)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: